Journal of Diabetes Investigation is a prestigious open-access journal published by WILEY, dedicated to advancing knowledge in the fields of Endocrinology, Diabetes, and Metabolism. With its ISSN 2040-1116 and E-ISSN 2040-1124, the journal provides a vital platform for researchers, healthcare professionals, and students to disseminate high-quality research, foster innovative ideas, and engage with cutting-edge developments in diabetes investigation. Since its inception in 2010, the journal has established a solid reputation, ranking in Q2 for Endocrinology and Diabetes and Metabolism, and Q1 for both Internal Medicine and Miscellaneous Medicine categories in 2023. Its Scopus rankings further underscore its impact, notably at the 76th percentile in Internal Medicine. The open access model, adopted in 2014, ensures that vital information is freely available, promoting global collaboration and knowledge sharing. The journal is not only a reflection of Australia's commitment to medical research but also a beacon for advancements that can ultimately enhance patient outcomes in diabetes care.

Journal of Endocrinology Metabolism and Diabetes of South Africa, published by Routledge Journals, Taylor & Francis Ltd, serves as a vital platform for advancing research and knowledge dissemination in the fields of endocrinology, metabolism, and diabetes. Since its transition to Open Access in 2012, it has enabled greater accessibility to crucial findings and data, broadening its reach to researchers, practitioners, and students alike. Though its coverage in Scopus was discontinued in 2018, the journal continues to play an important role in fostering discourse in the medical community, as evidenced by its ranking within the 19th and 16th percentiles for Internal Medicine and Endocrinology, diabetes and metabolism, respectively. With its commitment to addressing pressing health issues in South Africa and beyond, this journal remains an invaluable resource for those seeking to understand and tackle the complexities of metabolic diseases.

Nature Reviews Endocrinology is a premier journal published by NATURE PORTFOLIO, providing comprehensive and critical reviews in the rapidly evolving field of endocrinology. Established to foster advanced understanding, it has become a vital resource for researchers, professionals, and students alike. With an impressive impact factor and a prominent ranking of Q1 in both Endocrinology and Endocrinology, Diabetes, and Metabolism categories for 2023, the journal is recognized for its high-quality research dissemination, evidenced by its rankings of #2 out of 244 in Medicine and #2 out of 128 in Biochemistry, Genetics, and Molecular Biology. Spanning the years from 2009 to 2024, it focuses on publishing cutting-edge information that shapes current scientific knowledge and clinical practices. The journal offers open access options, ensuring greater visibility and reach for its articles. Located in Germany, this journal remains at the forefront of endocrinology research, significantly contributing to the understanding of hormonal functions and their implications on health. Discover the latest advancements and insights by exploring Nature Reviews Endocrinology.

Current Diabetes Reports is a leading academic journal published by CURRENT MEDICINE GROUP, dedicated to advancing research and clinical practices in the field of diabetes and endocrinology. With an impressive impact factor and ranked in the prestigious Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine, this journal serves as a vital resource for researchers, clinicians, and students alike. Established in 2001 and converging years up to 2024, Current Diabetes Reports aims to disseminate high-quality, peer-reviewed research articles, reviews, and clinical studies that address the multifaceted challenges of diabetes management and treatment. As it continues to thrive within a robust international community, the journal provides critical insights that are essential for improving patient outcomes and informing public health policies in the United States and beyond.

Clinical Medicine Insights-Endocrinology and Diabetes, published by SAGE Publications Ltd, is a dynamic open-access journal dedicated to advancing the field of endocrinology and diabetes through high-quality research. Since its inception in 2008, this journal has become an essential resource for researchers, healthcare professionals, and students interested in the latest innovations and clinical practices in the realm of diabetes management and endocrine disorders. With an impressive 2023 JCR Q2 ranking in both Endocrinology, Diabetes and Metabolism and Internal Medicine, the journal serves as a pivotal platform for scholarly discussions, focusing on the convergence of clinical insights and therapeutic advancements. By offering an open-access model, the journal ensures that its articles are accessible to a global audience, thus promoting the dissemination of knowledge and best practices in the treatment of these critical health issues. The journal's commitment to excellence is reflected in its Scopus rankings, which position it among the noteworthy publications in the field. As it converges from 2009 to 2024, Clinical Medicine Insights-Endocrinology and Diabetes remains a cornerstone for impactful research, inspiring collaborations and serving as a vital reference for ongoing developments in patient care and treatment methodologies.

Journal of Endocrinology and Metabolism is a dynamic and essential publication in the field of endocrinology, diabetes, and metabolism, published by ELMER PRESS INC in Canada. With an ISSN of 1923-2861 and E-ISSN 1923-287X, this journal serves as a pivotal platform for sharing innovative research and advancements from 2018 through 2024. Although categorized in the fourth quartile (Q4) for 2023, its commitment to high-quality research is reflected in its ongoing efforts to foster scholarly dialogue and illuminate critical issues within its scope. Targeting primarily researchers, healthcare professionals, and students, the journal aims to disseminate crucial findings that advance our understanding of endocrine functions and metabolic processes. Given its Scopus ranking of #207 out of 244 within its category, the Journal of Endocrinology and Metabolism continues to contribute to the global discourse on these vital health topics.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.

DIABETES, published by the American Diabetes Association, is a premier journal in the field of endocrinology, diabetes, and metabolism, renowned for its rigorous peer-reviewed research since its inception in 1952. With an impressive impact factor and classified in the Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine as of 2023, it holds a prestigious position within the scholarly community, ranked 17th out of 244 in its specialization. The journal's objective is to disseminate cutting-edge research and advance scientific understanding to ultimately improve diabetes patient care and management. While it does not offer open access options, the journal remains a vital resource for researchers, professionals, and students involved in diabetes-related studies. The ongoing dedication to excellence by the authors, reviewers, and editors ensures that DIABETES continues to be a pivotal platform for innovation and knowledge in the fight against diabetes.

Therapeutic Advances in Endocrinology and Metabolism is a premier open-access journal published by SAGE Publications Ltd that has established itself as a leading platform for research in the field of endocrinology, diabetes, and metabolism. With a commitment to disseminating high-quality research, the journal aims to advance our understanding of therapeutic interventions and innovations in the management of endocrine disorders. Since its inception in 2010, it has garnered a strong reputation, attaining a Q1 quartile ranking in 2023 in its category and boasting a respectable Scopus rank of #53 out of 244, positioning it within the 78th percentile. As an open-access journal since 2019, Therapeutic Advances in Endocrinology and Metabolism ensures that valuable research findings are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and students alike. The journal's multifaceted objectives encompass the publication of original research, reviews, and clinical studies that contribute to the evolving dialogue surrounding endocrine health. By delivering timely and robust content, it serves as an indispensable resource for those striving to make significant contributions to this vital area of medical science.

CURRENT DIABETES REVIEWS is a leading academic journal published by Bentham Science Publishers Ltd, dedicated to disseminating high-quality reviews and cutting-edge insights in the field of Endocrinology, Diabetes and Metabolism. Established in 1996 and actively publishing from 2005 to 2024, this journal holds a prestigious position within the academic community, evidenced by its Q2 ranking in both relevant categories for 2023 and its impactful presence in Scopus, where it ranks #83 out of 244 in Endocrinology and Diabetes and Metabolism. Despite being a subscription-based journal, it provides researchers, healthcare professionals, and students with valuable contributions that significantly advance the understanding of diabetes and related metabolic disorders. With a commitment to promoting interdisciplinary collaboration and innovation, CURRENT DIABETES REVIEWS serves as an essential resource for those seeking to stay abreast of the latest developments in diabetes research and therapies.